Palbociclib is the first CDK4/6 inhibitor received FDA approval for HR+, HER2– breast cancer treatment in 2015 whereas abemaciclib is the third approved CDK4/6 inhibitor (approved in 2018) [65]. This evidence concerns the gene CDK4 and breast cancer.